US Subsidiary vs. Contracted US Sponsor for FDA IDE Studies: Cost, Time, and Liability Compared

The Rule That Catches Non-US Device Companies Off Guard

Under 21 CFR 812.18(a), a company located outside the United States cannot itself act as the sponsor of an FDA Investigational Device Exemption (IDE) study. A US person, whether an individual or a legal entity, must assume that sponsor role and bear all obligations that flow from it, including submission of the IDE application, oversight of investigators, adverse event reporting, and recordkeeping under 21 CFR Parts 812 and 11. For the global device company that wants to run a pivotal or feasibility study in the United States, that single regulatory requirement creates an immediate structural question: do you form a US subsidiary, or do you contract with an established US sponsor of record?

Two Paths, Very Different Tradeoffs

A contracted US sponsor can be engaged and operational within days, requires no equity structure or state registration, and transfers defined regulatory accountability to an experienced entity without the overhead of staffing or compliance infrastructure; a US subsidiary, by contrast, typically takes months to incorporate, register with the FDA, hire qualified regulatory personnel, and establish the quality system procedures required to credibly hold sponsor obligations, and while it offers long-term strategic control, estimated formation and ongoing maintenance costs commonly range from tens of thousands to well over one hundred thousand dollars annually depending on state, headcount, and operational scope, making the contracted path significantly more capital-efficient for early-stage or single-study programs.

Understanding the Regulatory Weight of the Sponsor Role

The sponsor of an IDE study is not a figurehead. FDA regulations at 21 CFR 812.40 through 812.150 assign the sponsor direct responsibility for selecting qualified investigators, monitoring the study, reviewing adverse device effects, submitting required reports, and maintaining sponsor records for a minimum of two years after the study closes. For a significant risk device study, the sponsor must also obtain an approved IDE before enrollment begins. For nonsignificant risk devices, the sponsor makes the initial risk determination and documents it, but FDA oversight remains active through Institutional Review Board oversight and the abbreviated IDE requirements of 21 CFR 812.2(b).

A non US company that attempts to hold these obligations directly is not in compliance with 21 CFR 812.18(a), full stop. FDA has issued warning letters and placed clinical holds on studies where the sponsor identity did not meet this requirement. The stakes are not hypothetical.

Forming a US Subsidiary: Control at a Price

Some device companies, particularly those planning multiple US clinical programs or a US commercial launch, choose to incorporate a US subsidiary as a long-term investment. This approach gives the parent company direct control over regulatory strategy, IP ownership within the US entity, and the ability to build institutional knowledge in house.

However, the timeline is a genuine constraint. State incorporation can take two to eight weeks depending on jurisdiction, but establishing the entity as a credible IDE sponsor requires more: FDA registration where applicable, a functioning quality management system that addresses 21 CFR Part 820 requirements, written procedures for sponsor oversight, and personnel with documented qualifications. Realistically, a non US company should budget six to twelve months before a newly formed subsidiary is positioned to submit an IDE application and withstand FDA scrutiny. Cost estimates for formation, legal fees, registered agent services, and initial staffing commonly range from tens of thousands of dollars for a bare-bones structure to well over one hundred thousand dollars per year for a properly staffed regulatory entity. These figures are estimates only and will vary materially based on state, legal counsel, and operational choices.

Contracted US Sponsor of Record: Speed and Defined Liability

A contracted US sponsor of record, sometimes called a regulatory sponsor of record or US agent sponsor, assumes the FDA-facing obligations of 21 CFR Part 812 on behalf of the non US company under a formal contractual agreement. The non US company retains scientific and operational control over the study while the contracted sponsor holds the IDE, signs submissions, and interfaces with FDA as the responsible US party.

ADB Consulting and CRO Inc. provides this service directly. For current US Sponsor of Record initiation fees, please refer to the published schedule at adbccro.com/us-sponsor, which reflects ADB's current pricing at the time of this writing. Fees and scope are clearly defined before engagement, with no ambiguity about what is covered.

Speed is the most immediate advantage. A contracted sponsor arrangement can be documented, executed, and communicated to FDA within days, not months. For a company facing an enrollment window, an investor milestone, or a competitive timeline, that difference is often decisive.

Liability under this structure is shared and defined by contract. The contracted sponsor bears FDA-facing regulatory liability for the IDE as filed. The non US company retains liability for the accuracy of the information it provides, device safety data, and adherence to the agreed protocol. Legal counsel should review the allocation carefully before execution.

Which Path Is Right for Your Program?

Consider the following factors when reviewing your options with your regulatory team:

• Timeline: If your IDE submission needs to move within weeks, a contracted sponsor is the only realistic option.
• Budget stage: Pre-Series B companies preparing for a first-in-human or feasibility study rarely have the runway to absorb subsidiary formation costs without dilution.
• Long-term US strategy: If you anticipate a 510(k) or PMA submission, a US commercial entity, and ongoing post-market studies, a subsidiary may be worth building in parallel while using a contracted sponsor for the immediate program.
• Regulatory complexity: Significant risk IDE studies with complex protocols benefit from a contracted sponsor that has existing FDA relationships and submission infrastructure.

ADB Consulting and CRO Inc. is the only FDA-licensed US Sponsor of Record CRO that combines full IDE sponsorship with in-house clinical trial management, regulatory affairs, and post-market surveillance support under one roof.

Reviewed October 20, 2026 by ADB's Regulatory Team

Frequently Asked Questions

Can a non US company be listed as a co-sponsor on an FDA IDE to share the regulatory burden?

FDA regulations at 21 CFR 812.18(b) do permit co-sponsorship arrangements, but at least one sponsor must be a US person as required by 21 CFR 812.18(a). The non US entity cannot hold the primary sponsor designation. Any co-sponsor arrangement should be reviewed by qualified regulatory counsel before the IDE is submitted, as FDA will assess whether the US sponsor has genuine oversight capacity and cannot simply be a nominal listing.

Does using a contracted US sponsor of record affect who owns the IDE data or the device intellectual property?

IDE ownership and data rights are contractual matters, not directly governed by 21 CFR Part 812. The contracted sponsor holds the IDE application as the FDA-recognized sponsor, but the underlying clinical data, device design history, and IP remain with the non US company as defined in the services agreement. Your legal team should prepare explicit data ownership, license, and transfer provisions before the contract is executed to avoid ambiguity if the relationship changes during or after the study.

What happens to an active IDE if the contracted US sponsor relationship is terminated mid-study?

FDA requires that an IDE study have an active, responsible US sponsor at all times. If a contracted sponsor relationship ends during an active study, the sponsorship must be formally transferred to a new US person before the study can continue enrolling. This transfer requires written notification to FDA and to each participating investigator under 21 CFR 812.18(b). Planning for this scenario in the original services agreement, including transition timelines and data handover procedures, is essential risk management that any experienced contracted sponsor should help you address at the outset.

Ready to Move Forward?

If your team is preparing to assess the right US sponsor structure for an upcoming IDE study, ADB Consulting and CRO Inc. is ready to help you review your options and build a regulatory strategy that fits your timeline and budget. Visit adbccro.com/us-sponsor to review current service details and initiation fees, or book a free discovery call with Andre Butler's team today.

For related guidance, see our US Sponsor of Record program.